title: Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
authors.forename: F
authors.initials: F
authors.lastname: Palandri
authors.forename: M
authors.initials: M
authors.lastname: Amabile
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: G
authors.initials: G
authors.lastname: Bandini
authors.forename: F
authors.initials: F
authors.lastname: Benedetti
authors.forename: E
authors.initials: E
authors.lastname: Usala
authors.forename: E
authors.initials: E
authors.lastname: Angelucci
authors.forename: M
authors.initials: M
authors.lastname: Tiribelli
authors.forename: R
authors.initials: R
authors.lastname: Fanin
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000328:Adult; D001549:Benzamides; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D014184:Transplantation, Homologous
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate